The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2020 | The role of CAR T-cell therapy in DLBCL
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses the impact of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). CAR T-cell therapy represents an important and promising tool for patients that have failed previous treatment strategies. Dr Sureda reveals that a significant proportion of patients still relapse after CAR T-cell therapy and outlines the strategies to overcome this challenge. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.
